Please login to the form below

Precision medicine from concept to clinic

In our latest edition of ‘Perspective’ magazine, we examine the challenges and opportunities for several stakeholders impacted by the dawn of precision medicine

In this edition of ‘Perspective ’, the magazine of Blue Latitude Health, we examine the challenges and opportunities that have risen with the dawn of precision medicine.

The emergence of new targeted therapies and diagnostic tests have led to a more complex network of stakeholders than ever before. Now, industry is working with new players who each have a variety of needs, challenges and pain points.

We have spoken to these stakeholders to chart their journeys and the role they play in ensuring patients can access precision medicines. Read on to hear from patients, healthcare professionals, scientists, those transforming healthcare systems, diagnostic experts, and executives at innovative pharmaceutical companies.

Find out their personal stories and gain a behind-the-scenes look at the role they play in driving novel healthcare innovations. Once you have learned from these first-hand accounts, turn to our precision medicine ecosystem, which begins on p.50 . Here, we reveal key insights to help you meet the needs of seven core stakeholders involved in launching and delivering precision medicines.

Blue Latitude Health works with commercial and medical teams in top pharmaceutical companies and innovative biotechs. Our capabilities, from insight and strategy to creative execution, ensure we can solve our clients’ end-to-end commercial challenges. Our early stage service is specifically designed to help launch cutting-edge products, ensuring our clients make a real difference in patients’ lives.

Download the publication to learn:

* An overview of how precision medicine is impacting stakeholders across the precision medicine ecosystem

* Breast cancer patient Laura Holmes Haddad’s story of taking part in a novel PARP inhibitor clinical trial

* Laura oncologist gives his perspective of the PARP inhibitor clinical trial along with his advice for industry

* What it’s like to treating paediatric patients with CAR-T at Great Ormond Street Children’s hospital

* How Genomics England is rolling out precision medicine across the nation

* Nancy Brandt explains how a top biopharma company is transforming internally to ensure it sits at the forefront of innovation

* Insights from seven key stakeholders, from payers and regulators, to healthcare technology, diagnostic companies, pharmaceuticals, healthcare professionals and patients.

Download the full publication here

31st May 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world
Our parent company, Fishawack Health has reorganized to deliver agile and innovative solutions for life-sciences companies in the face of rapidly changing markets
Blue Latitude Health
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health